Literature DB >> 23338214

Benzodiazepine-like substances and hepatic encephalopathy : implications for treatment.

J A Cossar1, P C Hayes, R E O'Carroll.   

Abstract

Hepatic encephalopathy is a neuropsychiatric syndrome that can complicate acute and chronic liver disease. Recent research has focused on the role benzodiazepine-like substances play in the pathogenesis of this disorder. It has been proposed that potentiation of the action of the neuroinhibitory transmitter γr-aminobutyric acid (GABA) through the binding of endogenous benzodiazepine agonists to the benzodiazepine receptor binding site accounts for the clinical and biochemical features of this condition.Increased levels of endogenous benzodiazepine-like substances have been noted in animal models of hepatic encephalopathy. In human studies, levels of these substances of up to 10 times those found in the body fluids of nonencephalopathic controls have been reported. The existence of such markedly elevated levels cannot be satisfactorily explained with reference to possible pharmaceutical or dietary origins.Further support for the role of benzodiazepines in the mediation of hepatic encephalopathy comes from the therapeutic effect reported after administration of the benzodiazepine receptor antagonist flumazenil. Improvements in the severity of hepatic encephalopathy have been documented in rats with fulminant hepatic failure given flumazenil, although results have been inconsistent according to the dose of flumazenil used and the procedure employed to induce the encephalopathy. Transient, but distinct, improvements in the grade of hepatic encephalopathy have also been documented in several human studies. In a placebo-controlled study involving patients with mild hepatic encephalopathy, a low dose of flumazenil (0.2 mg/kg) resulted in a significant improvement in reaction time.Research now needs to identify whether the beneficial effect of flumazenil is due to its antagonistic or inverse agonistic properties, and also to clarify the mechanisms by which the differential response to the drug in animal models of fulminant hepatic failure is mediated.

Entities:  

Year:  1997        PMID: 23338214     DOI: 10.2165/00023210-199708020-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  49 in total

1.  Persisting benzodiazepine metabolites responsible for the reaction to the benzodiazepine antagonist flumazenil in patients with hepatic encephalopathy.

Authors:  R Meier; K Gyr; A Scholer
Journal:  Gastroenterology       Date:  1991-07       Impact factor: 22.682

2.  Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure.

Authors:  A S Basile; R D Hughes; P M Harrison; Y Murata; L Pannell; E A Jones; R Williams; P Skolnick
Journal:  N Engl J Med       Date:  1991-08-15       Impact factor: 91.245

3.  Hepatic encephalopathy: lack of changes of gamma-aminobutyric acid content in plasma and cerebrospinal fluid.

Authors:  F Moroni; O Riggio; V Carlà; V Festuccia; F Ghinelli; I R Marino; M Merli; L Natali; G Pedretti; F Fiaccadori
Journal:  Hepatology       Date:  1987 Sep-Oct       Impact factor: 17.425

4.  Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy.

Authors:  A S Basile; S H Gammal; K D Mullen; E A Jones; P Skolnick
Journal:  J Neurosci       Date:  1988-07       Impact factor: 6.167

5.  Plasma GABA, GABA-like activity and the brain GABA-benzodiazepine receptor complex in rats with chronic hepatic encephalopathy.

Authors:  J E Maddison; P R Dodd; M Morrison; G A Johnston; G C Farrell
Journal:  Hepatology       Date:  1987 Jul-Aug       Impact factor: 17.425

6.  Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy.

Authors:  M Olasmaa; J D Rothstein; A Guidotti; R J Weber; S M Paul; S Spector; M L Zeneroli; M Baraldi; E Costa
Journal:  J Neurochem       Date:  1990-12       Impact factor: 5.372

7.  The GABAA receptor complex in hepatic encephalopathy. Autoradiographic evidence for the presence of elevated levels of a benzodiazepine receptor ligand.

Authors:  A S Basile; N L Ostrowski; S H Gammal; E A Jones; P Skolnick
Journal:  Neuropsychopharmacology       Date:  1990-02       Impact factor: 7.853

8.  The contribution of endogenous benzodiazepine receptor ligands to the pathogenesis of hepatic encephalopathy.

Authors:  A S Basile
Journal:  Synapse       Date:  1991-02       Impact factor: 2.562

9.  Hepatic encephalopathy in rats with thioacetamide-induced acute liver failure is not mediated by endogenous benzodiazepines.

Authors:  A Püspök; A Herneth; P Steindl; P Ferenci
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

10.  Treatment of cirrhotic hepatic encephalopathy with L-dopa. A controlled trial.

Authors:  H Michel; M Solere; P Granier; G Cauvet; J P Bali; F Pons; H Bellet-Hermann
Journal:  Gastroenterology       Date:  1980-08       Impact factor: 22.682

View more
  1 in total

Review 1.  Neuropsychological aspects of liver disease and its treatment.

Authors:  R E O'Carroll
Journal:  Neurochem Res       Date:  2007-10-24       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.